The nation’s most prescribed oral COVID-19 treatment — which reduced COVID-19 hospitalizations and deaths by 89 percent in a phase 2/3 study — has nearly 3 million orders with more than 1 million prescriptions filled, according to a June 1 HHS report.
The deal “will allow Pfizer to increase supply by an additional 4 million packs of Paxlovid, allowing us to meet global demand and help increase overall access,” Pfizer spokesperson Julia Cohen told The Hill.
